Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions
Continued here:
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Recommendation and review posted by G. Smith
